TransMedics Group (NASDAQ: TMDX) reported Q1 EPS of $0.35, $0.38 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $96.85 million versus the consensus estimate of $83.76 million.

Outlook:

TransMedics Group sees FY2024 revenue of $390-400 million, versus the consensus of $366.9 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.